Atlantic Coastal Acquisition Corp. II Completes Business Combination with Abpro Corporation

Abra Financial Holdings to Go Public via SPAC Merger with New Providence Acquisition Corp. III

March 16, 2026

Financial Services

Abra Financial Holdings announced plans to become a publicly traded company through a business combination with special purpose acquisition company New Providence Acquisition Corp. III. The deal values Abra at a $750 million pre-money equity valuation and is expected to provide growth capital, with shares expected to trade on Nasdaq under ticker ABRX after closing.

Astellas Pharma to Acquire Propella Therapeutics

November 15, 2023

Biotechnology

Astellas Pharma, through a US subsidiary, has entered into a merger agreement to acquire Propella Therapeutics for approximately $175 million in cash. Propella is developing PRL-02 (abiraterone decanoate), a next-generation long-acting prodrug targeting prostate cancer, which is currently in Phase 1 with plans to enter Phase 2a in 2024.

Ligand Pharmaceuticals Spins Off OmniAb and Merges With Avista Public Acquisition Corp. II

October 24, 2022

Biotechnology

Ligand Pharmaceuticals has signed a definitive merger agreement to spin off its OmniAb antibody discovery business into a newly formed standalone public company, OmniAb, Inc., via a Reverse Morris Trust. OmniAb will then merge with Avista Public Acquisition Corp. II (APAC), backed by Avista Capital Partners, with the combined company expected to be renamed OmniAb, Inc. and listed on Nasdaq.

OceanTech Acquisitions I Corp and Captura Biopharma Sign Definitive Business Combination Agreement

August 10, 2022

Biotechnology

OceanTech Acquisitions I Corp., a special purpose acquisition company, signed a definitive merger agreement with Captura Biopharma to take the biotech company public. The combined company is expected to operate under the name Captura Biopharma Holdings, Inc. and remain listed on Nasdaq, subject to SEC, regulatory, and stockholder approvals.

Alvotech Holdings S.A. Business Combination with Oaktree Acquisition Corp. II (Nasdaq ALVO)

June 15, 2022

Healthcare Services

Alvotech completed its business combination with Oaktree Acquisition Corp. II, sponsored by an affiliate of Oaktree Capital Management, and began trading on Nasdaq on June 16 under the ticker ALVO. The deal created a publicly traded, pureplay global biosimilars platform, supported by an upsized $175 million PIPE and additional commitments tied to the transaction structure.

SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

October 20, 2021

Biotechnology

SAB Biotherapeutics entered into a definitive business combination/merger agreement with Big Cypress Acquisition Corp. (a SPAC), with the combined company to operate as SAB Biotherapeutics and be listed on Nasdaq. Big Cypress stockholders approved the deal, and the transaction was expected to close on or about October 22, 2021, subject to customary conditions.